| Literature DB >> 23448774 |
Kei Suzuki1, Hiroyasu Oda, Yumiko Sugawara, Masahiro Masuya, Kazunori Nakase, Masaki Fujioka, Hiroshi Imai, Naoyuki Katayama.
Abstract
We herein report the case of a 77-year-old woman who developed acute thrombocytopenia during the 23rd cycle of modified FOLFOX therapy. She developed a hypersensitivity reaction with nasal bleeding. The chemotherapy infusion was immediately discontinued. The patient's symptoms resolved with discontinuation of chemotherapy and the administration of supportive therapy. A complete blood count showed severe thrombocytopenia, and oxaliplatin-induced thrombocytopenia was diagnosed. The patient was admitted to the hospital, and the thrombocytopenia was corrected with a platelet transfusion followed by prednisolone. She was discharged after one week without requiring additional platelet transfusions. With the widespread use of oxaliplatin, the risk of oxaliplatin-induced acute thrombocytopenia should be considered an acute onset hematological emergency.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23448774 DOI: 10.2169/internalmedicine.52.8933
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271